Shares of Emergent Biosolutions Inc. (NYSE:EBS) rose 2.2% on Tuesday . The stock traded as high as $27.69 and last traded at $27.59, with a volume of 169,082 shares changing hands. The stock had previously closed at $26.99.

EBS has been the topic of several recent analyst reports. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Wednesday, June 22nd. Zacks Investment Research raised Emergent Biosolutions from a “sell” rating to a “hold” rating in a research note on Monday, July 4th. Singular Research dropped their price objective on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, June 28th. JPMorgan Chase & Co. dropped their price objective on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating on the stock in a research note on Friday, August 5th. Finally, Cowen and Company reissued a “hold” rating and issued a $33.00 price objective on shares of Emergent Biosolutions in a research note on Sunday, August 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $40.00.

The company has a market cap of $1.16 billion, a price-to-earnings ratio of 20.45 and a beta of 1.24. The stock has a 50-day moving average price of $27.72 and a 200 day moving average price of $34.37.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. Emergent Biosolutions had a net margin of 11.61% and a return on equity of 11.93%. The company earned $101.49 million during the quarter, compared to the consensus estimate of $111.20 million. During the same quarter in the prior year, the company posted $0.36 earnings per share. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. On average, equities analysts anticipate that Emergent Biosolutions Inc. will post $1.03 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in EBS. State Street Corp raised its stake in Emergent Biosolutions by 23.3% in the first quarter. State Street Corp now owns 1,099,602 shares of the biopharmaceutical company’s stock worth $39,969,000 after buying an additional 208,084 shares during the period. Renaissance Technologies LLC raised its stake in Emergent Biosolutions by 16.9% in the first quarter. Renaissance Technologies LLC now owns 1,112,811 shares of the biopharmaceutical company’s stock worth $40,451,000 after buying an additional 161,200 shares during the period. Aperio Group LLC raised its stake in Emergent Biosolutions by 25.7% in the first quarter. Aperio Group LLC now owns 10,542 shares of the biopharmaceutical company’s stock worth $383,000 after buying an additional 2,154 shares during the period. Fisher Asset Management LLC raised its stake in Emergent Biosolutions by 2.2% in the second quarter. Fisher Asset Management LLC now owns 467,770 shares of the biopharmaceutical company’s stock worth $14,253,000 after buying an additional 10,028 shares during the period. Finally, HBK Investments L P acquired a new stake in Emergent Biosolutions during the first quarter worth approximately $947,000. Institutional investors and hedge funds own 89.95% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

5 Day Chart for NYSE:EBS

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.